USPTO Examiner MILLIGAN ADAM C - Art Unit 1612

Recent Applications

Detailed information about the 100 most recent patent applications.

Application NumberTitleFiling DateDisposal DateDispositionTime (months)Office ActionsRestrictionsInterviewAppeal
16972300COMBINATIONS OF BETA-LACTAM COMPOUNDS AND PROBENECID AND USES THEREOFDecember 2020September 2022Allow2141YesNo
17097465TREATMENT AND PREVENTION OF BONE LOSS USING RESOLVINSNovember 2020February 2024Abandon3930NoNo
17084506Grip Enhancing Compositions, and Methods and Uses ThereofOctober 2020November 2022Abandon2510NoNo
17051767MICROSPHERE FOR EMBOLIZATION, PREPARATION METHOD THEREOF, AND METHOD FOR EMBOLIZING TUMOR USING THE SAMEOctober 2020September 2024Abandon4611NoNo
17049476ORALLY DISINTEGRATING TABLETS COMPRISING GLYCOPYRROLATE AND METHODS FOR INCREASING BIOAVAILABILITYOctober 2020June 2023Abandon3220NoNo
17069303MEDICINAL DELIVERY SYSTEM AND RELATED METHODSOctober 2020June 2023Abandon3220NoNo
16963846GEL PRODUCT INSTANT-DISSOLVING BLOCK AND PREPARATION METHOD THEREOFJuly 2020September 2022Allow2541YesNo
16954329COMPOSITION COMPRISING GLUCOSYLATED TERPENE GLYCOSIDES, TERPENE GLYCOSIDES AND CYCLODEXTRINEJune 2020April 2024Abandon4630NoYes
16839703ORGANIC COMPOUNDSApril 2020November 2021Abandon2010NoNo
16822320Masking Bitter FlavorsMarch 2020December 2022Abandon3310YesNo
16803982BIOCIDAL SURFACEFebruary 2020July 2021Abandon1710YesNo
16780365MARKERS FOR PHARMACEUTICALSFebruary 2020September 2022Abandon3220NoYes
16629532FIBROUS POLYMER MATERIAL COMPRISING FIBROIN AND POLYMER SCAFFOLDS COMPRISING THEREOFJanuary 2020April 2023Abandon3901NoNo
16720892TIME RELEASED BIODEGRADABLE OR BIOERODIBLE MICROSPHERES OR MICROPARTICLES SUSPENDED IN A SOLIDIFYING DEPOT-FORMING INJECTABLE DRUG FORMULATIONDecember 2019February 2023Abandon3810NoNo
16687972TABLET AND METHOD FOR MANUFACTURING THE SAMENovember 2019October 2023Abandon4721YesNo
16688924Oral Medicine Delivery CapsuleNovember 2019August 2023Abandon4550YesNo
16683663Oral Care Compositions Comprising CharcoalNovember 2019July 2023Abandon4420NoNo
16612653COMPOSITION FOR DISINTEGRATING TABLETS CONTAINING MICROFIBROUS CELLULOSE AND ACTIVE INGREDIENTNovember 2019September 2023Abandon4620YesNo
16656674COMPOSITION COMPRISING CHARCOAL AND AN EXTRACT OR SUBSTANCE OF ASTROCARYUM MURUMURUOctober 2019May 2023Abandon4320YesNo
16599827ORAL CARE FORMULATION SYSTEM PROVIDING AMORPHOUS CALCIUM PHOSPHATEOctober 2019November 2022Abandon3720NoNo
16603969DISPENSING CAP CONTAINING A SOLUBILISATE OF A PHARMACEUTICALLY ACTIVE AGENT OR DIETARY SUPPLEMENTOctober 2019June 2023Abandon4441NoNo
16570184Oral Therapeutic Compound Delivery SystemSeptember 2019March 2023Abandon4230YesYes
16566696Oral Dosage Forms Of Methyl Hydrogen Fumarate And Prodrugs ThereofSeptember 2019December 2023Abandon5160YesNo
16489786MULTI-DOMAIN VESICLE COMPRISING IMMUNOSUPPRESSIVE FACTOR CONTROL MATERIAL, PRODUCTION METHOD THEREFOR AND IMMUNOMODULATORY COMPOSITION COMPRISING SAMEAugust 2019October 2022Abandon3831NoNo
16489781MULTI-DOMAIN VESICLE COMPRISING IMMUNOACTIVE MATERIAL, PRODUCTION METHOD THEREFOR AND IMMUNOMODULATORY COMPOSITION COMPRISING SAMEAugust 2019October 2022Abandon3831NoNo
16553056PHARMACEUTICAL CARRIER IN THE PREPARATION OF AN ANTI-DIABETIC PHARMACEUTICAL COMPOSITION AND METHODS FOR TREATMENTAugust 2019January 2023Allow4141YesNo
16524952REDUCED DOSE METAXALONE FORMULATIONSJuly 2019March 2024Abandon5680YesYes
16474882USE OF SUBLINGUAL DEXMEDETOMIDINE FOR THE TREATMENT OF AGITATIONJune 2019September 2023Allow5060YesNo
16474028ADMINISTRATION OF ANTIBIOTIC COMPOUNDS FOR THE TREATMENT OF STREPTOCOCCAL INFECTIONS FOR THE TREATMENT OF PSORIASISJune 2019September 2023Abandon5141NoYes
16471519MAGNESIUM/LITHIUM PREPARATIONS FOR NEUROPROTECTION AND NEUROTROPHIC BENEFITSJune 2019September 2021Allow2721YesNo
16444360METHODS AND COMPOSITIONS FOR MAKING AND USING NANOTHERAPEUTIC DRUG DELIVERY VEHICLESJune 2019September 2023Abandon5141YesNo
16440907MULTIPARTICULATES OF SPRAY-COATED DRUG AND POLYMER ON A MELTABLE COREJune 2019May 2021Allow2330NoYes
16469593A CO-AMORPHOUS FORM OF A SUBSTANCE AND A PROTEINJune 2019June 2023Abandon4841YesNo
16468862HAIR COMPOSITION COMPRISING A GUANIDINE SALT, AN ALKANOLAMINE, AMMONIUM HYDROXIDE AND A POLYOLJune 2019August 2023Abandon5031YesNo
16398210ANAEROBIC ANTIOXIDANT COMPOSITIONApril 2019January 2024Abandon5750YesNo
16341670APPETITE CONTROL DEVICEApril 2019January 2023Abandon4510NoNo
16338152A NEW DRUG DELIVERY SYSTEM FOR TREATMENT OF DISEASEMarch 2019February 2021Abandon2311NoNo
16274357ORGANIC COMPOUNDSFebruary 2019May 2020Abandon1510NoNo
16261444LIMITED RELEASE LINGUAL THIOCTIC ACID DELIVERY SYSTEMSJanuary 2019July 2022Allow4260YesNo
16247605METHOD OF PREPARING PHARMACEUTICAL MICROSPHEREJanuary 2019November 2020Abandon2310NoNo
16240642INTRANASAL DELIVERY OF LEVODOPA POWDER BY PRECISION OLFACTORY DEVICEJanuary 2019December 2021Abandon3621NoNo
16239222Alcohol-Resistant FormulationsJanuary 2019January 2020Abandon1310NoNo
16312692PHARMACEUTICAL PREPARATION FOR DELIVERY OF PEPTIDES AND PROTEINSDecember 2018December 2020Abandon2410YesNo
16220619ORALLY DISINTEGRATING TABLET HAVING INNER COREDecember 2018October 2020Abandon2220YesNo
16216552WOOD PRESERVATIVE AND METHOD FOR PRODUCING SAMEDecember 2018June 2022Abandon4250YesNo
16169952Grip Enhancing Compositions, and Methods and Uses ThereofOctober 2018December 2020Abandon2620NoNo
16084542TABLETSeptember 2018February 2023Abandon5350YesNo
16084173FORMULATIONS FOR TREATING CONSTIPATIONSeptember 2018December 2023Abandon6001NoNo
16102711LIMITED RELEASE LINGUAL THIOCTIC ACID DELIVERY SYSTEMSAugust 2018July 2021Abandon3521NoNo
16038450SURFACE TREATED LIPID SUPPORTED MULTILAYERSJuly 2018November 2022Abandon5251YesNo
16067458Enteric coated oral pharmaceutical preparation comprising dimethyl fumarateJune 2018January 2023Abandon5540YesNo
16005330PHARMACEUTICAL COMPOSITION, PHARMACEUTICAL DOSAGE FORM, PROCESS FOR THEIR PREPARATION, METHODS FOR TREATING AND USES THEREOFJune 2018April 2022Abandon4631NoNo
15992494PARTICLES, COMPOSITIONS AND METHODS FOR OPHTHALMIC AND/OR OTHER APPLICATIONSMay 2018August 2020Abandon2601NoNo
15975577INJECTABLE SUSTAINED RELEASE COMPOSITION AND METHOD OF USING THE SAME FOR TREATING INFLAMMATION IN JOINTS AND PAIN ASSOCIATED THEREWITHMay 2018August 2021Allow4040YesNo
15770825PYRIMIDINE COMPOSITIONS, ULTRA-PURE COMPOSITIONS AND SALTS THEREOF, METHODS OF MAKING THE SAME, AND METHODS OF USING THE SAME FOR TREATING HISTAMINE H4 RECEPTOR (H4) MEDIATED DISEASES AND CONDITIONSApril 2018January 2021Abandon3320NoNo
15955397ADMINISTRATION OF BENZODIAZEPINE COMPOSITIONSApril 2018April 2021Abandon3620YesYes
15941419ANTIMICROBIALS AND METHODS OF USE THEREOF FOR WOUND HEALINGMarch 2018August 2019Abandon1630NoNo
15934595ORAL FORMULATIONS OF DEFERASIROXMarch 2018May 2023Abandon6020YesYes
15927703FULLERENE AND ITS USE TO MAINTAIN GOOD HEALTH AND TO PROLONG THE EXPECTED LIFESPAN OF MAMMALSMarch 2018June 2022Allow5141YesNo
15758953ARGININE-CONTAINING RESTORATIVE DENTAL MATERIALS AND METHODS OF PREVENTING AND CONTROLLING CARIES ASSOCIATED WITH DENTAL WORKMarch 2018November 2020Abandon3311NoNo
15914244MICRONEEDLE ARRAYMarch 2018March 2022Abandon4940YesNo
15913279TREATMENT AND PREVENTION OF BONE LOSS USING RESOLVINSMarch 2018January 2021Abandon3420NoNo
15912640GAMMA-HYDROXYBUTYRIC ACID GRANULESMarch 2018March 2022Abandon4931YesNo
15752951COMPOSITION FOR SKIN WHITENING COMPRISING BETA-MANGOSTIN AS EFFECTIVE INGREDIENTFebruary 2018December 2023Allow6041YesYes
15879806RAPID DISSOLVE TABLET COMPOSITIONS FOR VAGINAL ADMINISTRATIONJanuary 2018January 2020Abandon2410NoNo
15736792MICRO-NANO MEDICAL ADSORBENT RESIN POWDER MATERIALDecember 2017November 2020Abandon3611NoNo
15834537Oral Care CompositionsDecember 2017June 2023Abandon6051NoNo
15834160Oral Care CompositionsDecember 2017June 2023Abandon6051NoNo
15577362COSMETICSNovember 2017August 2021Abandon4530NoNo
15822762PROCESS FOR MAKING A COATED DOSAGE FORMNovember 2017November 2023Abandon6080NoNo
15814067INJECTABLE SUSTAINED RELEASE COMPOSITION AND METHOD OF USING THE SAME FOR TREATING INFLAMMATION IN JOINTS AND PAIN ASSOCIATED THEREWITHNovember 2017November 2018Abandon1210NoNo
15814197INJECTABLE SUSTAINED RELEASE COMPOSITION AND METHOD OF USING THE SAME FOR TREATING INFLAMMATION IN JOINTS AND PAIN ASSOCIATED THEREWITHNovember 2017November 2018Abandon1210NoNo
15566740POLYMERS FOR STABILISING PEROXIDE COMPOUNDSOctober 2017September 2022Abandon5941YesNo
15566230Whitening Systems for Hydrophobic Whitening GelsOctober 2017August 2021Allow4621NoNo
15711510COMPOSITION FOR REMOVING DENTAL PLAQUE AND TARTARSeptember 2017January 2021Allow4021YesNo
15708556Oral Care Compositions and Methods of UseSeptember 2017June 2021Allow4531YesNo
15700432HAIR CARE COMPOSITIONS COMPRISING GLYCERIDE COPOLYMERSSeptember 2017December 2020Abandon3921NoNo
15684226Oral Care CompositionsAugust 2017May 2022Allow5741NoYes
15680241TAMPER RESISTANT DOSAGE FORMSAugust 2017August 2019Abandon2410NoNo
15670522HYLA3D HYALURONIC ACID ACTIVATING LIP COMPLEXAugust 2017January 2020Allow2921YesNo
15548468Oral Care Compositions and Methods of UseAugust 2017March 2024Abandon6061NoYes
15548272Oral Care Compositions and Methods of UseAugust 2017September 2023Abandon6081NoNo
15661705METHODS AND COMPOSITIONS FOR ENHANCING IMMUNE RESPONSEJuly 2017November 2019Abandon2820NoNo
15649861PROCESS FOR MAKING ORAL CARE COMPOSITIONSJuly 2017January 2022Abandon5571NoNo
15646102ORALLY DISINTEGRATING TABLET AND METHOD FOR PRODUCING SAMEJuly 2017November 2020Abandon4041YesNo
15646617OPHTHALMIC DEVICES FOR SUSTAINED DELIVERY OF ACTIVE COMPOUNDSJuly 2017November 2020Abandon4021NoYes
15634579Organic CompoundsJune 2017March 2019Abandon2010NoNo
15539753METHOD FOR PRODUCING LIQUID COMPOSITION FOR ORAL CAVITY AND LIQUID COMPOSITION FOR ORAL CAVITYJune 2017November 2020Allow4141YesNo
15539748Zinc Phosphate Complex for Oral CareJune 2017February 2024Allow6080YesYes
15539725Zinc Phosphate ComplexJune 2017February 2023Allow6060YesYes
15539230Oral Care Compositions and Methods of UseJune 2017May 2024Allow6080YesYes
15538330Zinc Phosphate ComplexJune 2017February 2024Allow6080NoYes
15537975Oral Care CompositionJune 2017April 2020Abandon3440NoNo
15625863ORAL FORMULATIONS OF DEFERASIROXJune 2017October 2020Abandon4040YesYes
15533710Oral Care CompositionJune 2017September 2022Abandon6040NoYes
15533697Oral Care CompositionJune 2017September 2022Abandon6080NoNo
15613432Implantable Metallic Sheet for Bone RepairJune 2017November 2019Abandon3021YesNo
15600732Method of preparing albumin nanoparticle carrier wrapping taxane drugMay 2017April 2019Allow2330YesNo
15596875RAPID DISPERSE DOSAGE FORMMay 2017May 2018Abandon1270NoNo
15521058Preparation of Zinc Citrate and of Zinc Citrate-Containing Oral Care CompositionsApril 2017August 2021Allow5260YesNo

Appeals Overview

This analysis examines appeal outcomes and the strategic value of filing appeals for examiner MILLIGAN, ADAM C.

Patent Trial and Appeal Board (PTAB) Decisions

Total PTAB Decisions
45
Examiner Affirmed
29
(64.4%)
Examiner Reversed
16
(35.6%)
Reversal Percentile
57.4%
Higher than average

What This Means

With a 35.6% reversal rate, the PTAB reverses the examiner's rejections in a meaningful percentage of cases. This reversal rate is above the USPTO average, indicating that appeals have better success here than typical.

Strategic Value of Filing an Appeal

Total Appeal Filings
119
Allowed After Appeal Filing
23
(19.3%)
Not Allowed After Appeal Filing
96
(80.7%)
Filing Benefit Percentile
25.1%
Lower than average

Understanding Appeal Filing Strategy

Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.

In this dataset, 19.3% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is below the USPTO average, suggesting that filing an appeal has limited effectiveness in prompting favorable reconsideration.

Strategic Recommendations

Appeals to PTAB show good success rates. If you have a strong case on the merits, consider fully prosecuting the appeal to a Board decision.

Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.

Examiner MILLIGAN, ADAM C - Prosecution Strategy Guide

Executive Summary

Examiner MILLIGAN, ADAM C works in Art Unit 1612 and has examined 507 patent applications in our dataset. With an allowance rate of 20.3%, this examiner allows applications at a lower rate than most examiners at the USPTO. Applications typically reach final disposition in approximately 46 months.

Allowance Patterns

Examiner MILLIGAN, ADAM C's allowance rate of 20.3% places them in the 3% percentile among all USPTO examiners. This examiner is less likely to allow applications than most examiners at the USPTO.

Office Action Patterns

On average, applications examined by MILLIGAN, ADAM C receive 3.33 office actions before reaching final disposition. This places the examiner in the 89% percentile for office actions issued. This examiner issues more office actions than most examiners, which may indicate thorough examination or difficulty in reaching agreement with applicants.

Prosecution Timeline

The median time to disposition (half-life) for applications examined by MILLIGAN, ADAM C is 46 months. This places the examiner in the 12% percentile for prosecution speed. Applications take longer to reach final disposition with this examiner compared to most others.

Interview Effectiveness

Conducting an examiner interview provides a +38.2% benefit to allowance rate for applications examined by MILLIGAN, ADAM C. This interview benefit is in the 85% percentile among all examiners. Recommendation: Interviews are highly effective with this examiner and should be strongly considered as a prosecution strategy. Per MPEP § 713.10, interviews are available at any time before the Notice of Allowance is mailed or jurisdiction transfers to the PTAB.

Request for Continued Examination (RCE) Effectiveness

When applicants file an RCE with this examiner, 5.9% of applications are subsequently allowed. This success rate is in the 3% percentile among all examiners. Strategic Insight: RCEs show lower effectiveness with this examiner compared to others. Consider whether a continuation application might be more strategic, especially if you need to add new matter or significantly broaden claims.

After-Final Amendment Practice

This examiner enters after-final amendments leading to allowance in 9.3% of cases where such amendments are filed. This entry rate is in the 10% percentile among all examiners. Strategic Recommendation: This examiner rarely enters after-final amendments compared to other examiners. You should generally plan to file an RCE or appeal rather than relying on after-final amendment entry. Per MPEP § 714.12, primary examiners have discretion in entering after-final amendments, and this examiner exercises that discretion conservatively.

Pre-Appeal Conference Effectiveness

When applicants request a pre-appeal conference (PAC) with this examiner, 14.0% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 26% percentile among all examiners. Note: Pre-appeal conferences show below-average success with this examiner. Consider whether your arguments are strong enough to warrant a PAC request.

Appeal Withdrawal and Reconsideration

This examiner withdraws rejections or reopens prosecution in 45.1% of appeals filed. This is in the 12% percentile among all examiners. Of these withdrawals, 24.3% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner rarely withdraws rejections during the appeal process compared to other examiners. If you file an appeal, be prepared to fully prosecute it to a PTAB decision. Per MPEP § 1207, the examiner will prepare an Examiner's Answer maintaining the rejections.

Petition Practice

When applicants file petitions regarding this examiner's actions, 70.5% are granted (fully or in part). This grant rate is in the 76% percentile among all examiners. Strategic Note: Petitions are frequently granted regarding this examiner's actions compared to other examiners. Per MPEP § 1002.02(c), various examiner actions are petitionable to the Technology Center Director, including prematureness of final rejection, refusal to enter amendments, and requirement for information. If you believe an examiner action is improper, consider filing a petition.

Examiner Cooperation and Flexibility

Examiner's Amendments: This examiner makes examiner's amendments in 0.2% of allowed cases (in the 51% percentile). This examiner makes examiner's amendments more often than average to place applications in condition for allowance (MPEP § 1302.04).

Quayle Actions: This examiner issues Ex Parte Quayle actions in 0.0% of allowed cases (in the 0% percentile). This examiner rarely issues Quayle actions compared to other examiners. Allowances typically come directly without a separate action for formal matters.

Prosecution Strategy Recommendations

Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:

  • Prepare for rigorous examination: With a below-average allowance rate, ensure your application has strong written description and enablement support. Consider filing a continuation if you need to add new matter.
  • Expect multiple rounds of prosecution: This examiner issues more office actions than average. Address potential issues proactively in your initial response and consider requesting an interview early in prosecution.
  • Prioritize examiner interviews: Interviews are highly effective with this examiner. Request an interview after the first office action to clarify issues and potentially expedite allowance.
  • Plan for RCE after final rejection: This examiner rarely enters after-final amendments. Budget for an RCE in your prosecution strategy if you receive a final rejection.
  • Plan for extended prosecution: Applications take longer than average with this examiner. Factor this into your continuation strategy and client communications.

Relevant MPEP Sections for Prosecution Strategy

  • MPEP § 713.10: Examiner interviews - available before Notice of Allowance or transfer to PTAB
  • MPEP § 714.12: After-final amendments - may be entered "under justifiable circumstances"
  • MPEP § 1002.02(c): Petitionable matters to Technology Center Director
  • MPEP § 1004: Actions requiring primary examiner signature (allowances, final rejections, examiner's answers)
  • MPEP § 1207.01: Appeal conferences - mandatory for all appeals
  • MPEP § 1214.07: Reopening prosecution after appeal

Important Disclaimer

Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.

No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.

Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.

Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.